MATTHEW KALONICK: Open Payments
NPI 1093586059 · BISMARCK, ND. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$382 in 19 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $104 · 2025 $382
Food & beverage: $382
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $76 |
| Amgen Inc. | 4 | $66 |
| Merck Sharp & Dohme LLC | 3 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Philips North America LLC | 1 | $33 |
| LeMaitre Vascular, Inc. | 1 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
| Novo Nordisk Inc | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
Products named: CAMZYOS, REPATHA, VERQUVO, AMVUTTRA, WAINUA, Ambulatory Monitoring & Diagnostics Undivided, HYDRO LEMAITRE VALVULOTOME, JARDIANCE.
Industry payments across ND — which companies pay providers there.
